miR-221 Promotes Tumorigenesis in Human Triple Negative Breast Cancer CellsRounak Nassirpour(Pfizer (United States)), Min-Jean Yin(Pfizer (United States))PLoS ONEApril 24, 201310.1371/journal.pone.0062170Cited by 93SaveCiteExport RISWatch citationsRelated PapersmiR-122 Regulates Tumorigenesis in Hepatocellular Carcinoma by Targeting AKT3|PLoS ONE|2013|102Targeting 3-Phosphoinoside-Dependent Kinase-1 to Inhibit Insulin-Like Growth Factor-I Induced AKT and p70 S6 Kinase Activation in Breast Cancer Cells|PLoS ONE|2012|15